Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).

被引：1

作者：

Larkin, James M. G.

McArthur, Grant A.

Ribas, Antoni

Ascierto, Paolo Antonio

Gallo, Jorge D.

Rooney, Isabelle Anne

Chang, Ilsung

Dreno, Brigitte

机构：

[1] Royal Marsden NHS Fdn Trust, London, England

[2] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia

[3] Univ Melbourne, East Melbourne, Vic, Australia

[4] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[5] Ist Nazl Tumori Fdn G Pascale, Naples, Italy

[6] F Hoffmann La Roche Ltd, Basel, Switzerland

[7] Genentech Inc, San Francisco, CA 94080 USA

[8] Univ Nantes, Nantes, France

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.9528

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9528

引用

页数：2